Vaccine study to lower HPV spread in HPV-positive women
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older, and you can join through a routine cervical or gynecologic visit
- Your HPV test shows HPV16 and/or HPV18 (or double-positive), and your other high-risk HPV types are negative
- You were recently told you have HPV16/18 (within the last 10 months)
- You fit one of these situations: no visible cervix lesion, mild/moderate cervix lesion (CIN1/2) that can be watched, certain HPV-related anal situations, or certain HPV-related vulvar problems
- You do not need a procedure for a cervix lesion that would affect the cervix within the next 7 months
- You are not pregnant and do not plan to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a single dose of the HPV vaccine (Gardasil 9) can lower the amount of HPV virus in women who already have the virus, potentially reducing how easily it spreads. It will help us learn if vaccination can protect partners and communities.
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
This study tests a 9-valent HPV vaccine (protects against 9 types of human papillomavirus) in women who have already completed a previous HPV vaccine series. Researchers will check how safe the new vaccine is and how well your immune system responds to it.
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
Hear when a new Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.